Gibson Oncology: Funding, Investors & Team (Sep 2026)
Gibson Oncology acquired the Indenos with the aim of making a positive impact on cancer patients' lives in two key areas. Firstly, Indenos are designed to combat cancer resistance by maintaining high drug concentrations within cancer cells, making it difficult for the cells to remove the drug and evade destruction. Secondly, Indenos have a favorable side effect profile, offering cancer patients a better quality of life during treatment with minimal severe side effects. The company believes that these drugs can effectively target resistant cancers in both children and adults, aligning with their goal of fighting cancer without compromising patient well-being. Their planned Phase II trials are geared towards this purpose.
Gibson Oncology has raised $250k across 1 funding round on record, the most recent an undisclosed round of $250k announced in Jul 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Gibson Oncology Company Profile and Key Stats
Latest funding round on record: Jul 2025.
Gibson Oncology Funding Rounds
Gibson Oncology Founders and Leadership Team
No contact details are on record for this team yet.
Gibson Oncology Funding Compared to Other Biotechnology Startups
Gibson Oncology's latest round of $250k is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Gibson Oncology in Biotechnology and Miami
Companies Similar to Gibson Oncology
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Gibson Oncology Funding FAQs
What does Gibson Oncology do?
Gibson Oncology acquired the Indenos with the aim of making a positive impact on cancer patients' lives in two key areas. Firstly, Indenos are designed to combat cancer resistance by maintaining high drug concentrations within cancer cells, making it difficult for the cells to remove the drug and evade destruction. Secondly, Indenos have a favorable side effect profile, offering cancer patients a better quality of life during treatment with minimal severe side effects. The company believes that these drugs can effectively target resistant cancers in both children and adults, aligning with their goal of fighting cancer without compromising patient well-being. Their planned Phase II trials are geared towards this purpose.
How much funding has Gibson Oncology raised?
Gibson Oncology has raised $250k across 1 round on record. The most recent is an undisclosed round of $250k announced in Jul 2025.
When did Gibson Oncology last raise funding?
Gibson Oncology's most recent funding round on record is an undisclosed round of $250k, announced in Jul 2025.
Who founded Gibson Oncology?
FundedIQ lists Elizabeth L Rogers (Founder) at Gibson Oncology.
Where is Gibson Oncology headquartered?
Gibson Oncology is based in Miami, Florida, United States.
How many employees does Gibson Oncology have?
Gibson Oncology is in the 1-10 employee band.
How does Gibson Oncology's funding compare to other Biotechnology startups?
Gibson Oncology's latest round of $250k is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Gibson Oncology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Gibson Oncology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.